Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
ASTELLAS PHARMA
🇯🇵
Japan
Country
🇯🇵
Japan
Ownership
-
Established
2005-01-01
Employees
-
Market Cap
$22.5B
Website
https://www.astellas.com/
Clinical Trials
Related News
Drug Use-Results Survey of Betanis Tablets in Japan
Completed
Conditions
Overactive Bladder
Interventions
Drug: Betanis
Subscribe
First Posted Date
2013-08-08
Last Posted Date
2015-10-05
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
10711
Registration Number
NCT01919047
Subscribe
Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder
Phase 1
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: FK949E
Subscribe
First Posted Date
2013-08-08
Last Posted Date
2024-10-31
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
16
Registration Number
NCT01919008
Subscribe
Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers
Phase 1
Completed
Conditions
Healthy
Pharmacokinetics of Quetiapine
Interventions
Drug: FK949E
Drug: fluvoxamine
Subscribe
First Posted Date
2013-07-25
Last Posted Date
2017-02-16
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
24
Registration Number
NCT01908296
Subscribe
Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis
Completed
Conditions
Chronic Renal Failure
Interventions
Drug: bixalomer
Subscribe
First Posted Date
2013-07-19
Last Posted Date
2024-10-22
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
123
Registration Number
NCT01903213
Subscribe
Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder
Phase 1
Completed
Conditions
Major Depressive Disorder Patients
Interventions
Drug: FK949E
Subscribe
First Posted Date
2013-07-19
Last Posted Date
2017-02-16
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
16
Registration Number
NCT01903200
Subscribe
A Study to Evaluate Safety and Tolerability of a Therapeutic Vaccine, ASP0113, in Subjects Undergoing Allogeneic Hematopoietic Cell Transplant
Phase 2
Completed
Conditions
Allogeneic Hematopoietic Cell Transplant
Interventions
Biological: ASP0113
Subscribe
First Posted Date
2013-07-19
Last Posted Date
2024-10-17
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
9
Registration Number
NCT01903928
Subscribe
Long-Term Specified Drug Use-results Survey of Betanis Tablets
Completed
Conditions
Overactive Bladder
Interventions
Drug: Betanis
Subscribe
First Posted Date
2013-07-17
Last Posted Date
2016-11-01
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
1263
Registration Number
NCT01901120
Subscribe
Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients
Completed
Conditions
Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis
Interventions
Drug: Kiklin capsules
Subscribe
First Posted Date
2013-07-17
Last Posted Date
2017-01-27
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
1078
Registration Number
NCT01901107
Subscribe
Specified Drug Use-results Survey of Betanis Tablets
Completed
Conditions
Overactive Bladder
Interventions
Drug: mirabegron
Subscribe
First Posted Date
2013-07-12
Last Posted Date
2018-02-05
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
300
Registration Number
NCT01898624
Subscribe
Specified Drug Use-Results Survey of Regnite
Completed
Conditions
Restless Legs Syndrome
Interventions
Drug: Regnite
Subscribe
First Posted Date
2013-06-27
Last Posted Date
2019-04-29
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
1597
Registration Number
NCT01887613
Subscribe
Prev
1
9
10
11
12
13
52
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy